Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families
- PMID: 28814538
- PMCID: PMC5621635
- DOI: 10.1542/peds.2016-1159D
Implications of the FMR1 Premutation for Children, Adolescents, Adults, and Their Families
Abstract
Background and objectives: Given the nature of FMR1 gene expansions, most biological mothers, and often multiple other family members of children with fragile X syndrome (FXS), will have a premutation, which may increase individual and family vulnerabilities. This article summarizes important gaps in knowledge and notes potential implications for pediatric providers with regard to developmental and medical risks for children and adolescents with an FMR1 premutation, including possible implications into adulthood.
Methods: A structured electronic literature search was conducted on FMR1 pre- and full mutations, yielding a total of 306 articles examined. Of these, 116 focused primarily on the premutation and are included in this review.
Results: Based on the literature review, 5 topic areas are discussed: genetics and epidemiology; phenotypic characteristics of individuals with the premutation; implications for carrier parents of children with FXS; implications for the extended family; and implications for pediatricians.
Conclusions: Although the premutation phenotype is typically less severe in clinical presentation than in FXS, premutation carriers are much more common and are therefore more likely to be seen in a typical pediatric practice. In addition, there is a wide range of medical, cognitive/developmental, and psychiatric associated features that individuals with a premutation are at increased risk for having, which underscores the importance of awareness on the part of pediatricians in identifying and monitoring premutation carriers and recognizing the impact this identification may have on family members.
Copyright © by the American Academy of Pediatrics.
Conflict of interest statement
POTENTIAL CONFLICT OF INTEREST: Dr Mailick is the chair of the Scientific Advisory Board of the John Merck Fund Developmental Disabilities Program. Dr Hagerman has received funding from Novartis, Roche, Alcobra, and Neuren for treatment of fragile X syndrome, and she has consulted with Roche/Genentech and Novartis regarding fragile X treatment; the other authors have indicated they have no potential conflicts of interest to disclose.
Figures
References
-
- Crum-Bailey JM, Dennison DH, Weiner WJ, Hawley JS. The neurology and corresponding genetics of fragile X disorders: insights into the genetics of neurodegeneration. Future Neurol. 2013;8(2):225–235
-
- Kraan CM, Hocking DR, Bradshaw JL, et al. . Neurobehavioural evidence for the involvement of the FMR1 gene in female carriers of fragile X syndrome. Neurosci Biobehav Rev. 2013;37(3):522–547 - PubMed
Publication types
MeSH terms
Substances
Supplementary concepts
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
